Nifty
:
14371.90
Sensex
:
48878.54
-218.45 (-1.50%)
-746.22 (-1.50%)
Nifty
Sensex
:
:
14371.90
48878.54
-218.45 (-1.50%)
-746.22 (-1.50%)

Lupin Ltd.

Pharmaceuticals & Drugs - Global

Rating :
59/99

BSE: 500257 | NSE: LUPIN

NSE BSE
1079.25
22-Jan-2021
  • Open
  • High
  • Low
  • Previous Close
  •  1071.00
  •  1089.00
  •  1056.65
  •  1068.20
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2540352
  •  27299.55
  •  1122.30
  •  504.75

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 48,959.05
  • N/A
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 52,810.07
  • 0.56%
  • 3.85

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.88%
  • 0.52%
  • 10.14%
  • FII
  • DII
  • Others
  • 18.97%
  • 21.03%
  • 2.46%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.21
  • 3.38
  • 2.13

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.71
  • -7.66
  • -4.70

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -1.07
  • -23.79
  • -18.51

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 25.60
  • 23.17
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.08
  • 3.69
  • 2.83

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.80
  • 14.78
  • 14.16

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Net Sales
3,835.00
3,882.21
-1.22%
3,527.86
3,877.69
-9.02%
3,845.74
3,886.64
-1.05%
3,769.27
3,947.33
-4.51%
Expenses
3,253.83
3,241.64
0.38%
3,039.78
3,130.86
-2.91%
3,320.42
3,107.38
6.86%
3,340.17
3,265.72
2.28%
EBITDA
581.17
640.57
-9.27%
488.08
746.83
-34.65%
525.32
779.26
-32.59%
429.10
681.61
-37.05%
EBIDTM
15.15%
16.50%
13.84%
19.26%
13.66%
20.05%
11.38%
17.27%
Other Income
24.96
127.96
-80.49%
43.28
66.59
-35.01%
208.60
73.28
184.66%
93.59
40.20
132.81%
Interest
33.62
82.59
-59.29%
44.26
84.41
-47.57%
107.38
84.30
27.38%
88.60
78.46
12.92%
Depreciation
212.73
252.57
-15.77%
214.64
250.16
-14.20%
214.26
219.06
-2.19%
253.23
218.96
15.65%
PBT
359.78
-113.11
-
272.46
478.85
-43.10%
495.37
551.42
-10.16%
-107.82
82.17
-
Tax
146.70
69.52
111.02%
164.32
215.50
-23.75%
105.07
294.27
-64.29%
767.02
245.40
212.56%
PAT
213.08
-182.63
-
108.14
263.35
-58.94%
390.30
257.15
51.78%
-874.84
-163.23
-
PATM
5.56%
-4.70%
3.07%
6.79%
10.15%
6.62%
-23.21%
-4.14%
EPS
4.66
-2.81
-
2.36
6.70
-64.78%
8.60
6.40
34.38%
-18.44
-3.35
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
14,977.87
16,836.56
16,751.37
15,804.15
17,494.33
14,255.54
12,770.01
11,286.57
9,641.30
7,082.91
5,818.97
Net Sales Growth
-3.95%
0.51%
5.99%
-9.66%
22.72%
11.63%
13.14%
17.06%
36.12%
21.72%
 
Cost Of Goods Sold
5,433.96
4,962.72
4,436.67
4,733.76
4,660.97
4,010.21
3,806.16
3,485.50
3,221.50
2,364.87
2,060.99
Gross Profit
9,543.91
11,873.84
12,314.70
11,070.39
12,833.36
10,245.33
8,963.85
7,801.07
6,419.80
4,718.04
3,757.98
GP Margin
63.72%
70.52%
73.51%
70.05%
73.36%
71.87%
70.19%
69.12%
66.59%
66.61%
64.58%
Total Expenditure
12,954.20
14,362.21
14,082.44
12,656.64
13,001.19
10,570.19
9,150.42
8,283.78
7,371.41
5,638.20
4,641.13
Power & Fuel Cost
-
443.17
442.28
433.88
377.86
381.27
362.81
334.29
320.22
268.82
205.47
% Of Sales
-
2.63%
2.64%
2.75%
2.16%
2.67%
2.84%
2.96%
3.32%
3.80%
3.53%
Employee Cost
-
2,986.84
2,770.17
2,864.71
2,849.52
2,141.62
1,747.34
1,464.65
1,266.62
969.53
767.56
% Of Sales
-
17.74%
16.54%
18.13%
16.29%
15.02%
13.68%
12.98%
13.14%
13.69%
13.19%
Manufacturing Exp.
-
1,852.21
1,731.57
2,087.52
2,270.19
1,766.00
1,320.55
1,129.59
976.51
753.07
603.68
% Of Sales
-
11.00%
10.34%
13.21%
12.98%
12.39%
10.34%
10.01%
10.13%
10.63%
10.37%
General & Admin Exp.
-
2,798.71
3,302.60
1,219.96
1,306.27
1,195.98
806.87
810.53
692.06
471.23
325.19
% Of Sales
-
16.62%
19.72%
7.72%
7.47%
8.39%
6.32%
7.18%
7.18%
6.65%
5.59%
Selling & Distn. Exp.
-
1,080.45
1,206.60
1,150.61
1,252.77
870.29
835.48
775.26
709.62
647.88
547.48
% Of Sales
-
6.42%
7.20%
7.28%
7.16%
6.10%
6.54%
6.87%
7.36%
9.15%
9.41%
Miscellaneous Exp.
-
238.11
192.55
166.20
283.61
204.82
271.21
283.96
184.88
162.80
547.48
% Of Sales
-
1.41%
1.15%
1.05%
1.62%
1.44%
2.12%
2.52%
1.92%
2.30%
2.25%
EBITDA
2,023.67
2,474.35
2,668.93
3,147.51
4,493.14
3,685.35
3,619.59
3,002.79
2,269.89
1,444.71
1,177.84
EBITDA Margin
13.51%
14.70%
15.93%
19.92%
25.68%
25.85%
28.34%
26.60%
23.54%
20.40%
20.24%
Other Income
370.43
483.76
333.01
150.35
106.51
185.19
239.75
116.48
27.85
14.35
22.19
Interest
273.86
362.98
302.49
204.35
152.53
59.47
9.81
26.65
40.95
35.47
34.48
Depreciation
894.86
970.22
846.05
1,085.87
912.23
487.13
434.70
260.97
332.19
227.52
171.18
PBT
1,019.79
1,624.91
1,853.40
2,007.64
3,534.89
3,323.94
3,414.83
2,831.65
1,924.60
1,196.07
994.37
Tax
1,183.11
1,146.56
901.69
288.46
978.51
1,059.34
970.40
962.15
584.16
308.56
114.98
Tax Rate
116.02%
131.36%
59.58%
53.10%
27.68%
31.87%
28.42%
33.98%
30.35%
25.80%
11.56%
PAT
-163.32
-273.72
611.73
247.74
2,549.21
2,255.84
2,403.24
1,836.37
1,314.16
867.65
864.55
PAT before Minority Interest
-163.91
-273.72
611.73
254.83
2,556.38
2,264.60
2,444.43
1,869.50
1,340.44
887.51
879.39
Minority Interest
-0.59
0.00
0.00
-7.09
-7.17
-8.76
-41.19
-33.13
-26.28
-19.86
-14.84
PAT Margin
-1.09%
-1.63%
3.65%
1.57%
14.57%
15.82%
18.82%
16.27%
13.63%
12.25%
14.86%
PAT Growth
-193.52%
-
146.92%
-90.28%
13.00%
-6.13%
30.87%
39.74%
51.46%
0.36%
 
EPS
-3.60
-6.04
13.49
5.46
56.21
49.74
52.99
40.49
28.98
19.13
19.06

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
12,536.70
13,742.23
13,577.06
13,497.57
11,163.37
8,874.06
6,931.57
5,204.18
4,012.89
3,281.08
Share Capital
90.60
90.50
90.42
90.32
90.12
89.90
89.68
89.51
89.33
89.24
Total Reserves
12,231.40
13,433.31
13,275.26
13,233.50
10,958.87
8,728.15
6,815.66
5,107.79
3,920.76
3,190.59
Non-Current Liabilities
3,003.18
7,296.41
6,876.13
6,446.96
6,032.39
426.15
507.16
572.87
729.96
533.59
Secured Loans
0.70
358.82
448.03
217.15
5.55
12.50
24.42
37.95
27.76
54.25
Unsecured Loans
1,792.58
6,282.90
5,976.47
5,430.63
5,368.35
89.33
126.54
209.11
405.20
244.91
Long Term Provisions
296.29
370.79
356.85
308.73
190.00
162.03
132.49
112.45
77.02
37.28
Current Liabilities
9,225.20
6,129.87
5,095.55
6,120.59
5,061.17
3,729.23
2,629.55
3,006.92
3,120.30
2,507.37
Trade Payables
2,412.30
2,498.18
2,575.40
2,588.90
1,988.82
1,956.06
1,594.13
1,542.88
1,379.28
993.03
Other Current Liabilities
3,124.23
1,279.82
1,517.16
657.97
1,001.27
829.76
287.64
381.25
377.17
201.02
Short Term Borrowings
2,492.75
1,580.21
451.76
2,304.33
1,745.41
369.15
402.38
726.82
1,046.99
791.09
Short Term Provisions
1,195.92
771.66
551.23
569.39
325.67
574.26
345.40
355.97
316.86
522.23
Total Liabilities
24,809.54
27,215.37
25,588.82
26,099.64
22,289.01
13,053.54
10,135.22
8,843.42
7,935.44
6,373.55
Net Block
7,938.11
11,086.71
10,361.99
11,032.93
8,716.96
4,368.19
3,355.60
3,000.17
2,749.66
2,056.83
Gross Block
14,160.50
15,731.88
13,859.86
12,395.30
9,212.07
6,644.59
5,283.90
4,684.21
4,191.84
2,964.34
Accumulated Depreciation
6,222.39
4,645.17
3,497.87
1,362.37
495.11
2,276.40
1,928.30
1,684.04
1,442.18
907.51
Non Current Assets
9,396.33
13,361.79
13,379.28
14,146.71
12,401.61
5,221.19
4,034.77
3,700.29
3,593.12
2,869.33
Capital Work in Progress
939.62
1,639.71
2,598.20
2,133.06
2,702.40
551.87
285.90
310.70
434.84
478.17
Non Current Investment
36.07
185.63
26.71
22.00
14.33
2.51
2.06
2.06
2.80
3.15
Long Term Loans & Adv.
409.58
402.61
383.00
950.76
960.22
274.20
372.99
387.36
396.94
314.42
Other Non Current Assets
72.95
47.13
9.38
7.96
7.70
0.32
0.00
0.00
0.00
4.52
Current Assets
15,413.21
13,853.58
12,209.54
11,952.93
9,887.40
7,832.35
6,100.45
5,143.13
4,342.32
3,504.22
Current Investments
2,338.25
2,109.86
234.86
2,114.13
2.02
1,655.89
176.41
0.00
0.00
0.00
Inventories
3,456.87
3,836.77
3,662.49
3,642.28
3,273.65
2,503.56
2,129.45
1,948.93
1,732.67
1,199.96
Sundry Debtors
5,445.93
5,149.80
5,192.21
4,307.34
4,548.76
2,656.57
2,464.10
2,186.99
1,780.01
1,255.64
Cash & Bank
2,454.30
987.20
1,408.03
698.17
821.75
481.35
797.50
434.88
402.47
420.14
Other Current Assets
1,717.86
777.47
621.30
533.43
1,241.22
534.98
532.99
572.33
427.17
628.48
Short Term Loans & Adv.
1,180.53
992.48
1,090.65
657.58
761.78
294.91
275.15
339.67
306.12
515.64
Net Current Assets
6,188.01
7,723.71
7,113.99
5,832.34
4,826.23
4,103.12
3,470.90
2,136.21
1,222.02
996.85
Total Assets
24,809.54
27,215.37
25,588.82
26,099.64
22,289.01
13,053.54
10,135.22
8,843.42
7,935.44
6,373.55

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
1,468.84
1,665.97
1,751.19
4,113.51
-382.39
2,733.05
2,003.93
1,250.96
560.04
797.98
PBT
876.78
1,517.17
546.81
3,543.14
3,328.84
3,414.83
2,831.65
1,924.60
1,196.07
994.37
Adjustment
1,574.29
1,588.41
2,782.23
1,214.74
585.35
356.73
410.50
419.58
258.51
207.16
Changes in Working Capital
-471.02
-500.19
-1,019.43
504.62
-3,126.44
-94.91
-466.31
-549.35
-580.65
-159.56
Cash after chg. in Working capital
1,980.05
2,605.39
2,309.61
5,262.50
787.75
3,676.65
2,775.84
1,794.83
873.93
1,041.97
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-511.21
-939.42
-558.42
-1,148.99
-1,170.14
-943.60
-771.91
-543.87
-313.89
-243.99
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
1,106.99
-3,282.47
469.87
-2,527.44
-6,961.71
-1,054.51
-858.54
-521.86
-741.25
-519.56
Net Fixed Assets
-481.49
-462.56
-1,394.31
-876.24
480.96
-416.45
-309.36
-324.79
-389.71
-558.11
Net Investments
-67.96
-2,025.62
1,551.07
-3,173.10
-296.59
-2,280.57
-475.62
-0.75
-6.41
43.19
Others
1,656.44
-794.29
313.11
1,521.90
-7,146.08
1,642.51
-73.56
-196.32
-345.13
-4.64
Cash from Financing Activity
-890.58
744.13
-1,492.10
433.18
5,836.38
-196.89
-857.11
-662.82
108.86
-162.52
Net Cash Inflow / Outflow
1,685.25
-872.37
728.96
2,019.25
-1,507.72
1,481.65
288.28
66.28
-72.35
115.90
Opening Cash & Equivalents
544.06
1,416.43
687.47
780.22
2,095.06
606.62
310.93
244.65
295.88
164.22
Closing Cash & Equivalent
2,229.31
544.06
1,416.43
2,799.47
780.22
2,108.43
606.62
310.93
244.65
295.88

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
272.01
298.87
295.64
295.04
245.21
196.17
154.00
116.13
89.78
73.51
ROA
-1.05%
2.32%
0.99%
10.57%
12.82%
21.08%
19.70%
15.98%
12.40%
15.37%
ROE
-2.12%
4.55%
1.91%
20.98%
22.80%
31.09%
30.89%
29.12%
24.35%
30.08%
ROCE
6.02%
8.45%
3.54%
18.53%
24.38%
40.30%
40.97%
32.70%
24.40%
25.24%
Fixed Asset Turnover
2.12
1.93
2.07
1.62
1.80
2.15
2.28
2.19
1.99
2.10
Receivable days
60.97
66.11
63.76
92.39
92.24
72.65
74.67
74.61
77.76
74.26
Inventory Days
41.97
47.94
49.03
72.15
73.96
65.73
65.48
69.24
75.12
67.69
Payable days
65.89
68.49
68.56
59.62
63.20
64.43
63.78
63.76
64.11
61.46
Cash Conversion Cycle
37.04
45.56
44.23
104.91
103.00
73.94
76.37
80.10
88.76
80.49
Total Debt/Equity
0.51
0.63
0.53
0.60
0.65
0.06
0.09
0.22
0.41
0.35
Interest Cover
3.40
6.00
3.66
24.18
56.89
349.10
107.25
48.00
34.72
29.84

Annual Reports:

FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013
FY 2012
FY 2011

News Update:


  • Lupin gets tentative approval for Empagliflozin & Metformin Hydrochloride ER Tablets
    7th Jan 2021, 15:29 PM

    The product will be manufactured at Lupin's Nagpur facility in India

    Read More
  • Lupin gets USFDA’s approval for Sulfamethoxazole and Trimethoprim Oral Suspension
    6th Jan 2021, 16:33 PM

    Sulfamethoxazole and Trimethoprim Oral Suspension USP, 200 mg/40 mg per 5 mL, is indicated for the treatment and prevention of a wide variety of bacterial infections

    Read More
  • Lupin launches Mycophenolate Mofetil Tablets USP
    29th Dec 2020, 14:58 PM

    Mycophenolate Mofetil Tablets USP, 500 mg, are the generic equivalent of CellCept Tablets of Roche Palo Alto LLC

    Read More
  • Lupin launches Meloxicam Capsules
    28th Dec 2020, 14:56 PM

    Meloxicam Capsules (RLD: Vivlodex) had an annual sales of approximately $ 11 million in the U.S. (IQVIA MAT October 2020)

    Read More
  • Lupin receives tentative approval for Efinaconazole Topical Solution
    26th Dec 2020, 08:44 AM

    Efinaconazole Topical Solution, 10%, had estimated annual sales of $222.9 million in the US

    Read More
  • Lupin gets approval for Rufinamide Oral Suspension
    21st Dec 2020, 16:52 PM

    Rufinamide Oral Suspension, 40 mg/ml is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in pediatric patients 1 year of age and older, and in adults

    Read More
  • Lupin receives approval for Colesevelam Hydrochloride Tablets
    19th Dec 2020, 08:56 AM

    Colesevelam Hydrochloride Tablets (RLD: Welchol) had an annual sales of approximately $159 million in the US

    Read More
  • Lupin gets approval for Penicillamine Tablets USP
    1st Dec 2020, 14:21 PM

    The product would be manufactured at Lupin’s Nagpur facility

    Read More
  • Lupin launches Tacrolimus Capsules USP
    25th Nov 2020, 13:10 PM

    Tacrolimus Capsules USP, 0.5 mg, 1 mg, and 5 mg (RLD: Prograf) had an annual sales of approximately $303 million in the U.S.

    Read More
  • Lupin in alliance with Concord gets USFDA approval for Tacrolimus Capsules USP
    12th Nov 2020, 15:17 PM

    Tacrolimus Capsules USP are indicated for the prophylaxis of organ rejection in adult and pediatric patients

    Read More
  • USFDA concludes inspection of Lupin’s Somerset facility
    9th Nov 2020, 09:53 AM

    The inspection at the Somerset, NJ facility closed with thirteen observations

    Read More
  • Lupin experiences information security incident
    6th Nov 2020, 12:46 PM

    Restoration of the impacted systems is a priority and is underway

    Read More
  • Lupin reports Rs 211 crore consolidated net profit in Q2
    5th Nov 2020, 11:26 AM

    Total consolidated income of the company marginally decreased by 3.75% at Rs 3859.96 crore for Q2FY21

    Read More
  • Lupin - Quarterly Results
    4th Nov 2020, 22:54 PM

    Read More
  • Lupin wins five ‘INDIASTAR 2020’ awards for Excellence in Packaging
    24th Oct 2020, 09:18 AM

    The award was conferred by the Indian Institute of Packaging

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.